Search

Jeno Gyuris

from Lincoln, MA
Age ~65
Get Report
Also known as:
Jeno S
Phone and address:
139 Lexington Rd, Lincoln Center, MA 01773
(781) 259-0560
Related to:
Gyuris Gergely, 38Gerda Bacsa Gyuris, 61Adam Gyuris, 24
Connected to:
Jennifer Gyuris, 50Viktor S Gyuris, 56Roberta J Gyurisin, 65Gayane Gyurjyan, 33Patricia W Gyurke, 68Anita M Gyurko, 78Johanna M Gyuro, 65Timothy W Gyves, 75Dan Gzesh, 65Irwin I Gzesh, 70

Jeno Gyuris Phones & Addresses

  • 139 Lexington Rd, Lincoln, MA 01773 (781) 259-0560 (781) 729-9579
  • 171 Swanton St, Winchester, MA 01890 (781) 729-9579 (617) 729-9579
  • 171 Swanton St #5, Winchester, MA 01890 (781) 729-9579
  • 42 Hemlock St, Arlington, MA 02474
  • Nutting Lake, MA
  • 139 Lexington Rd, Lincoln, MA 01773 (781) 259-0560

Work

Company: Aveo pharmaceuticals Position: Svp

Education

Degree: Graduate or professional degree

Industries

Pharmaceuticals

Resumes

Resumes

Jeno Gyuris Photo 1

Svp At Aveo Pharmaceuticals

View page
Position:
svp at AVEO Pharmaceuticals
Location:
Greater Boston Area
Industry:
Pharmaceuticals
Work:
AVEO Pharmaceuticals
svp

Business Records

Name / Title
Company / Classification
Phones & Addresses
Jeno Gyuris
Senior Vice President; Chief Scientific Officer, Senior Vice President-drug Discovery
Aveo Pharmaceuticals, Inc
Mfg Pharmaceutical Preparations · Pharmaceutical Preparations · Research & Development in Biotechnology
75 Sidney St, Cambridge, MA 02139
64 Sidney St, Cambridge, MA 02139
(617) 299-5000, (617) 995-4827, (617) 995-4995

Publications

Us Patents

Methods And Regents For Identifying Synthetic Genetic Elements

View page
US Patent:
6342356, Jan 29, 2002
Filed:
Mar 10, 2000
Appl. No.:
09/522728
Inventors:
Jeno Gyuris - Winchester MA
Assignee:
GPC Biotech, Inc. - Waltham MA
International Classification:
C12Q 168
US Classification:
435 6, 435 691, 435 911, 435375, 435455, 536 231, 536 235, 536 245
Abstract:
The present invention relates to a selection method that allows fast recovery and identification of functional gene fragments which selectively inhibit growth, e. g. , are cytostatic or cytotoxic, of particular cell-types, such as transformed cells. The strategy relies, in part, on the ability of small gene fragments to encode dominant-acting synthetic genetic elements (SGEs), e. g. , molecules which interfere with the function of genes from which they are derived. SGEs which can be identified by the subject method include, but are not limited to, inhibitory antisense RNA molecules, ribozymes, nucleic acid decoys, and small peptides.

Methods And Reagents For Inhibiting Proliferation Of Smooth Muscle Cells

View page
US Patent:
6413943, Jul 2, 2002
Filed:
Dec 9, 1999
Appl. No.:
09/457568
Inventors:
James McArthur - San Carlos CA
Mitchell H. Finer - Woodside CA
Jeno Gyuris - Winchester MA
Assignee:
Cell Genesys, Inc. - Foster City CA
GPC Biotech Inc. - Waltham MA
International Classification:
A61K 4800
US Classification:
514 44, 4353201, 435325, 435352, 435366, 424 931, 424 9321, 536 231, 536 234
Abstract:
Disclosed are methods for using E1/E4 recombinant adenoviruses encoding cyclin dependent kinase inhibitors (CDKis) as reagents for inhibiting smooth muscle cell proliferation. Also disclosed are recombinant lentiviruses encoding cyclin dependent kinase inhibitors (CDKis).

Methods And Reagents For Isolating Biologically Active Peptides

View page
US Patent:
6420110, Jul 16, 2002
Filed:
Oct 19, 1998
Appl. No.:
09/174943
Inventors:
Jeno Gyuris - Winchester MA
Aaron J. Morris - Boston MA
Assignee:
GPC Biotech, Inc. - Waltham MA
International Classification:
C12Q 170
US Classification:
435 6, 435 5, 435 71, 435 691, 4352351, 435DIG 1, 435DIG 3, 435DIG 4, 435DIG 15
Abstract:
One aspect of the present invention is the synthesis of a binary method that combines variegated peptide display libraries, e. g. , in a âdisplay modeâ, with soluble secreted peptide libraries, e. g. , in a âsecretion modeâ, to yield a method for the efficient isolation of peptides having a desired biological activity.

Methods And Reagents For Inhibiting Angiogenesis

View page
US Patent:
6420345, Jul 16, 2002
Filed:
Dec 9, 1999
Appl. No.:
09/457646
Inventors:
Salil Patel - Cupertino CA
James McArthur - San Carlos CA
Jeno Gyuris - Winchester MA
Assignee:
Cell Genesys, Inc. - Foster City CA
GPC Biotech Inc. - Waltham MA
International Classification:
A61K 4800
US Classification:
514 44, 424 931, 424 9321, 435440, 435455, 435475, 435476, 4353201, 536 231
Abstract:
Disclosed are methods for inhibiting angiogenesis using cyclin dependent kinase inhibitors (CDKi) and fusion proteins thereof, recombinant viruses comprising transgenes and nucleic acid sequences encoding the same, and liposomes carrying the same as angiogenesis-inhibiting reagents.

Inhibitors Of Cell-Cycle Progression And Uses Related Thereto

View page
US Patent:
6495526, Dec 17, 2002
Filed:
Jul 29, 1997
Appl. No.:
08/902572
Inventors:
Jeno Gyuris - Winchester MA
Lou Lamphere - Boston MA
David H. Beach - Huntington Bay NY
Assignee:
GPC Biotech, Inc. - Waltham MA
International Classification:
A61K 4800
US Classification:
514 44, 536 234, 536 2372, 536 241
Abstract:
The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced.

Anti-Neoplastic Compositions And Uses Thereof

View page
US Patent:
6521602, Feb 18, 2003
Filed:
Mar 1, 2000
Appl. No.:
09/516065
Inventors:
Salil Patel - Cupertino CA
James McArthur - San Carlos CA
Jeno Gyuris - Winchester MA
Michael J. Mendez - El Granada CA
Mitchell H. Finer - Woodside CA
Assignee:
GPC Biotech Inc. - Waltham MA
Cell Genesys, Inc. - Foster City CA
International Classification:
A61K 4800
US Classification:
514 44, 424 932, 4353201, 435455, 435456, 536 231, 536 234, 536 2372
Abstract:
Disclosed is a nucleic acid composition consisting essentially of a first nucleic acid sequence encoding a chimeric CDKi protein and a second nudeic acid sequence encoding an adenovirus E4 protein, wherein the first and second nucleic acid sequences are operably linked to at least one regulatory sequence.

Hepatocyte Growth Factor (Hgf) Binding Antibody

View page
US Patent:
7649083, Jan 19, 2010
Filed:
Jun 1, 2007
Appl. No.:
11/757059
Inventors:
S. Kirk Wright - Waltham MA, US
May Han - Brookline MA, US
Lyne Breault - Roslindale MA, US
Jie Lin - West Roxbury MA, US
Christine Knuehl - Natick MA, US
Jeno Gyuris - Winchester MA, US
Arnold Horwitz - San Leandro CA, US
Assignee:
AVEO Pharmaceuticals, Inc. - Cambridge MA
XOMA Technology Ltd. - Berkeley CA
International Classification:
C07K 16/00
C07K 16/24
US Classification:
53038824, 5303871, 5303881, 53038815
Abstract:
The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.

Hepatocyte Growth Factor (Hgf) Binding Antibody

View page
US Patent:
7659378, Feb 9, 2010
Filed:
Jun 1, 2007
Appl. No.:
11/757094
Inventors:
May Han - Brookline MA, US
S. Kirk Wright - Waltham MA, US
Lyne Breault - Roslindale MA, US
Jie Lin - West Roxbury MA, US
Christine Knuehl - Natick MA, US
Jeno Gyuris - Winchester MA, US
Assignee:
AVEO Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C07K 16/00
C07K 16/24
US Classification:
53038823, 5303871, 5303881, 53038815
Abstract:
The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
Control profile
Jeno Gyuris from Lincoln, MA, age ~65 Get Report